With a market capitalization (market cap) of $1.88B — a measure of how much the company is worth — COMPASS Pathways plc is the 2155th most valuable company in Healthcare as of August 19, 2026. Shares trade at $13.90, up +1.31% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Visit websiteAs of August 19, 2026, COMPASS Pathways plc (CMPS) is worth $1.88B — this is its market capitalization, the total value of all its outstanding shares.
COMPASS Pathways plc’s market cap is $1.88B, which ranks it #2155 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
COMPASS Pathways plc (CMPS) shares trade at $13.90, up 1.31% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025